BioPharmSignal logoBioPharmSignal

Biotech News

Revolution Medicines Presents Overall Survival Data for RASONQUE™ (daraxonrasib) Across Subgroups in Previously Treated Metastatic Pancreatic Cancer at ESMO 2026

Revolution Medicines (RVMD)Revolution MedicinesClinical readout

Expanding on the unprecedented final results previously reported from the Phase 3 RASolute 302 trial, the exploratory subgroup analyses showed RASONQUE consistently provided an overall survival benefit compared with chemotherapy across key subgroups, including patients with no identified tumor RAS

Related news

RVMDRevolution Medicines2026-10-15 13:46 EST

Revolution Medicines’ RASONQUE(™) (daraxonrasib) Receives Positive CHMP Opinion Recommending Marketing Authorization in European Union for Metastatic Pancreatic Cancer

RVMDRevolution Medicines2026-10-05 12:00 EST

Revolution Medicines Begins Treating Patients in Phase 3 RASolute 309 Trial Evaluating RASONQUE™ (daraxonrasib) Plus Zoldonrasib as First-Line Treatment for Metastatic RAS G12D Pancreatic Cancer

IDYAIDEAYA Biosciences2026-10-23 10:00 EST

IDE849 (SHR-4849) DLL3 TOP1 ADC Updated Phase 1 Results at ESMO 2026 Demonstrates Promising Anti-Tumor Activity and Preliminary Overall Survival Results in Relapsed Small Cell Lung Cancer and Neuroendocrine Carcinomas

BNTXBioNTech2026-10-13 10:45 EST

BioNTech Provides Update on Phase 2/3 Clinical Trial for mRNA Cancer Immunotherapy Candidate BNT113 in Metastatic HPV16-positive Head and Neck Cancer

LYELLyell Immunopharma2026-09-10 20:05 EST

Lyell Immunopharma Completes Manufacturing Transfer for LYL273 and Provides Updated Timeline on Phase 1/2 Trial in Metastatic Colorectal Cancer

GSKGSK plc2026-10-18 19:36 EST

GSK presents first global data for Ris-Rez in extensive-stage small cell lung cancer

IMCRImmunocore Holdings plc2026-09-14 11:00 EST

Immunocore announces achievement of target enrollment in registrational TEBE-AM trial with KIMMTRAK® (tebentafusp) in previously treated advanced melanoma

GSKGSK plc2026-10-23 23:00 EST

GSK presents positive data for Mo-Rez in platinum-resistant ovarian cancer

REGNRegeneron Pharmaceuticals2026-10-06 11:00 EST

Regeneron Showcases Advances in Care Across Several Cancers and Cancer-associated Complications at ESMO 2026

CMPXCompass Therapeutics2026-10-24 08:15 EST

Compass Therapeutics Announces Publication of Phase 2/3 COMPANION-002 Results for Tovecimig in the Journal of Clinical Oncology and Oral Presentation at ESMO 2026

View all latest news

Revolution Medicines

RAS(ON) Inhibitors Revolution Medicines develops oral targeted therapies that bind active, GTP-loaded RAS proteins. Its portfolio covers multiple RAS mutations and combination strategies across pancreatic and lung cancers. Daraxonrasib Daraxonrasib is a multi-selective RAS(ON) inhibitor and the company's lead late-stage asset. It has...

Recent company news

RVMDRevolution Medicines2026-10-23 11:30 EST

Revolution Medicines Presents Overall Survival Data for RASONQUE™ (daraxonrasib) Across Subgroups in Previously Treated Metastatic Pancreatic Cancer at ESMO 2026

RVMDRevolution Medicines2026-10-21 20:05 EST

Revolution Medicines to Report Financial Results for Third Quarter 2026 After Market Close on November 4, 2026

RVMDRevolution Medicines2026-10-20 12:00 EST

Revolution Medicines Begins Treating Patients in Phase 3 RASolve 308 Trial Evaluating Zoldonrasib in Combination with Pembrolizumab and Chemotherapy as First-Line Treatment for Patients with Metastatic RAS G12D Non-Squamous Non-Small Cell Lung Cancer

RVMDRevolution Medicines2026-10-15 13:46 EST

Revolution Medicines’ RASONQUE(™) (daraxonrasib) Receives Positive CHMP Opinion Recommending Marketing Authorization in European Union for Metastatic Pancreatic Cancer

RVMDRevolution Medicines2026-10-05 12:00 EST

Revolution Medicines Begins Treating Patients in Phase 3 RASolute 309 Trial Evaluating RASONQUE™ (daraxonrasib) Plus Zoldonrasib as First-Line Treatment for Metastatic RAS G12D Pancreatic Cancer

Stock data

Close
187.69 USD
Market cap
32.17B USD
Exchange
NASDAQ
Sector
Biopharma
Location
United States